Home > Protocol Summaries: Compounds > GSK2248761

Protocol Summaries: GSK2248761

GSK Study ID	Phase	Title	Status
113020	phase 2	A Proof of Concept Study for GSK2248761 (An Extension of NV-05A-002: A Phase I/IIa Double-Blind Study to Evaluate the Safety and Tolerability, Antiretroviral Activity, Pharmacokinetics and Pharmacodynamics of IDX12899 in Antiretroviral Treatment-Naive HIV-1 Infected Subjects, completed by Idenix)	Completed
113045	phase 1	A Phase I Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 Pharmacokinetics and to Assess the Effect of GSK2248761 on CYP450 Probe Drugs in Healthy Adult Subjects	Completed
113391	phase 1	A single-center, randomized, two part, open-label, crossover study to assess the relative bioavailability and food effect of new formulations of GSK2248761 in healthy adult subjects	Completed
113392	phase 1	A Phase I, Open Label, Single Sequence, Drug Interaction Study Evaluating Plasma GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects.	Completed
113393	phase 1	An Open Label, Single dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 200 mg, Administered as an Oral Suspension to Healthy Adult Subjects	Terminated
113394	phase 1	A Double-Blind study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Drospirenone and Ethinyl Estradiol when Co-administered with GSK2248761 in Healthy Adult Female Subjects	Terminated
113399	phase 2	A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance	Terminated
113404	phase 2	Phase 2b study to select a once daily oral dose of GSK2248761 administered with tenofovir/emtricitabine or abacavir/lamivudine in HIV-1 infected antiretroviral therapy naive adult subjects	Terminated
113818	phase 1	A Phase I, single-center, drug interaction study between simvastatin, atorvastatin, rosuvastatin, and GSK2248761 in healthy subjects.	Completed
114122	phase 1	A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers	Suspended
114435	phase 1	A single-center, randomized, open-label, crossover study to assess the relative bioavailability of tablet formulations of GSK2248761 in healthy adult subjects. SGN114435	Completed